A prospective clinical trial to assess the efficacy of radioiodine ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer undergoing sub-total thyroidectomy

References

• Baldet L, Manderscheid JC, Glinoer D, Jaffiol C, Coste-Seignovert B, Percheron C. The management of differentiated thyroid cancer in Europe in 1988: Results of an international survey. Acta Endocrinol (Copenh) 1989; 120: 547–58
   PubMedGoogle Scholar
• Mazzaferri EL. Treating DTC. Where do we draw the line?. Mayo Clin Proc 1991; 66: 105–11
   PubMedGoogle Scholar
• Wong JB, Kaplan MM, Meyer KB, Pauker SG. Ablative 131I therapy for apparently localized thyroid carcinoma: A decision analytic perspective. Endocrinol Metab Clin North Am 1990; 19: 741–60
   PubMed Web of Science ®Google Scholar
• Singer PA, Cooper DS, Daniels GH, Ladenson PW, Greenspan FS, Levy EG, et al. Treatment guidelines for patients with thyroid nodules and well differentiated thyroid cancer American Thyroid Association. Arch Intern Med 1996; 156: 2165–72
   PubMed Web of Science ®Google Scholar
• Schroder DM, Chambors A, France CJ. Operative strategy for thyroid cancer: Is total thyroidectomy worth the price?. Cancer 1986; 58: 2320–8
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Young RL. Papillary thyroid carcinoma: A 10-year follow-up report of the impact of therapy in 576 patients. Am J Med 1981; 70: 511–8
   PubMed Web of Science ®Google Scholar
• Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: A retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987; 102: 1088–95
   PubMed Web of Science ®Google Scholar
• Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB. Papillary and follicular thyroid cancer: Impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988; 14: 1063–75
   PubMed Web of Science ®Google Scholar
• Thomas SR, Maxon HR, Kereiakes JG, Saenger EL. Quantitative external counting techniques enabling improved diagnostic and therapeutic decisions in patients with well differentiated thyroid cancer. Radiology 1977; 122: 731–7
   PubMedGoogle Scholar
• Brown MC, Spencer R. Thyroid gland volume estimated by use of ultrasound in addition to scintigraphy. Acta Radiol Oncol Radiat Phys Biol 1978; 17: 337–41
   PubMed Web of Science ®Google Scholar
• Snyder J, Gorman C, Scanlon P. Thyroid remnant ablation: Questionable pursuit of an ill-defined goal. J Nucl Med 1983; 24: 659–65
   PubMedGoogle Scholar
• Bal CS, Padhy AK, Jana S, Pant GS, Basu AK. Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996; 77: 2574–80
   PubMed Web of Science ®Google Scholar
• Vassilopoulou-Sellin R, Klein MJ, Smith TH, Samaan NA, Frankenthaler RA, Goepfert H, et al. Pulmonary metastases in children and young adults with differentiated thyroid cancer. Cancer 1993; 71: 1348–52
   PubMed Web of Science ®Google Scholar
• Bal CS, Kumar A, Chandra P, Dwivedi SN, Mukhopadhyaya S. Is chest X-ray or high resolution computed tomography scan of chest sufficient investigation to detect pulmonary metastasis in pediatric differentiated thyroid cancer. Thyroid 2000; 414: 221–9
   Google Scholar
• Goldman JM, Line BR, Aamodt RL, Robbins J. Influence of triiodothyronine withdrawal time on 131-I uptake postthyroidectomy for thyroid cancer. J Clin Endocrinol Metab 1980; 50: 734–9
   PubMed Web of Science ®Google Scholar
• Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, et al. Serum thyroglobulin autoantibodies: Prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998; 83: 1121–7
   PubMed Web of Science ®Google Scholar
• Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab 1998; 83: 4116–22
   PubMed Web of Science ®Google Scholar
• DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71: 414–24
   PubMed Web of Science ®Google Scholar
• Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA, et al. The results of various modalities of treatment of well differentiated thyroid carcinoma: A retrospective review of 1599 patients. J Clin Endocrinol Metab 1992; 75: 714–20
   PubMed Web of Science ®Google Scholar
• Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985; 55: 794–804
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418–28
   PubMed Web of Science ®Google Scholar
• Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297–306
   PubMed Web of Science ®Google Scholar
• Freitas JE, Gross MD, Ripley S, Shapiro B. Radionuclide diagnosis and therapy of thyroid cancer: Current status report. Semin Nucl Med 1985; 15: 106–31
   PubMedGoogle Scholar
• Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86: 1447–63
   PubMed Web of Science ®Google Scholar
• Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, et al. Outcome after treatment of high risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med 1998; 129: 622–7
   PubMedGoogle Scholar
• DiRusso G, Kern KA. Comparative analysis of complications from I-131 radioablation for well differentiated thyroid cancer. Surgery 1994; 116: 1024–30
   PubMed Web of Science ®Google Scholar
• Maxon HR, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS. Radioiodine-131 therapy for well differentiated thyroid cancer- a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992; 33: 1132–6
   PubMed Web of Science ®Google Scholar
• Bal CS, Kumar A, Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab 2004; 89: 1666–73
   PubMed Web of Science ®Google Scholar
• Lin JD, Chao TC, Huang MJ, Weng HF, Tzen KY. Use of radioactive iodine for thyroid remnant ablation in well-differentiated thyroid carcinoma to replace thyroid reoperation. Am J Clin Oncol 1998; 21: 77–81
   PubMedGoogle Scholar
• Burmeister LA, DuCret RP, Mariash CN. Local reactions to radioiodine in the treatment of thyroid cancer. Am J Med 1992; 90: 217–22
   Google Scholar
• Allweiss P, Braunstein GD, Katz A, Waxman A. Sialadenitis following I-131 therapy for thyroid carcinoma: Concise communication. J Nucl Med 1984; 25: 755–8
   PubMedGoogle Scholar